USSTOCK.TODAY
Weekend. Closed Log in Sign up

Lakefront Biotherapeutics NV ADR(LKFT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

LKFT
LKFT
Lakefront Biotherapeutics NV ADR
At close Nov 20 at 4:00 PM ET (Korea 11/21 06:00)
$33.31
-0.08 ▼ -0.24%
Nov 20 at 4:26 PM ET (Korea 11/21 06:26)
$33.31
+0.00 +0.00%
Channel Up Resistance 35.35 Support 30.09 Holding Same lines for 4 days

AI-drawn chart patterns are for reference only.

Full metrics table

Index ⓘ -P/E ⓘ 2.37EPS (ttm) ⓘ 14.06Insider Own ⓘ 25.35%Shs Outstand ⓘ 65.7MPerf Week ⓘ -1.97%
Market Cap ⓘ 2.19BForward P/E ⓘ -EPS next Y ⓘ -37.37%Insider Trans ⓘ -Shs Float ⓘ 49.0MPerf Month ⓘ 6.08%
Enterprise Value ⓘ -0.29BPEG ⓘ -EPS next Q ⓘ -0.7Inst Own ⓘ 25.79%Short Float ⓘ 2.65%Perf Quarter ⓘ 14.7%
Income ⓘ 0.93BP/S ⓘ 2.03EPS this Y ⓘ -132.44%Inst Trans ⓘ 5.37%Short Ratio ⓘ 4.62Perf Half Y ⓘ 21.17%
Sales ⓘ 1.08BP/B ⓘ 0.6EPS next 5Y ⓘ -ROA ⓘ 23.38%Short Interest ⓘ 1.30MPerf YTD ⓘ 1.87%
Book/sh ⓘ 55.93P/C ⓘ 0.88EPS past 3/5Y ⓘ -ROE ⓘ 28.1%52W High ⓘ -8.08% ($36.24)Perf Year ⓘ 10.15%
Cash/sh ⓘ 37.77P/FCF ⓘ -Sales past 3/5Y ⓘ 70.43% 18.16%ROIC ⓘ 25.22%52W Low ⓘ 29.71% ($25.68)Perf 3Y ⓘ -10.91%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 288.92%Gross Margin ⓘ 98.05%Volatility(W/M) ⓘ 2.12% 2.41%Perf 5Y ⓘ -35.27%
Dividend TTM ⓘ -EV/Sales ⓘ -0.27Sales Y/Y TTM ⓘ 240.77%Oper. Margin ⓘ 64.52%ATR (14) ⓘ 0.88Perf 10Y ⓘ -44.24%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 46.39EPS Q/Q ⓘ 98.69%Profit Margin ⓘ 85.89%RSI (14) ⓘ 57.02Recom ⓘ 2.5
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 46.49Sales Q/Q ⓘ -89.52%SMA20 ⓘ 0.39% ($33.18)Beta ⓘ 0.18Target Price ⓘ $35.44
Payout ⓘ -Debt/Eq ⓘ 0Earnings ⓘ 2026/11/11SMA50 ⓘ 7.4% ($31.01)Rel Volume ⓘ 0.58Prev Close ⓘ $33.39
Employees ⓘ 452LT Debt/Eq ⓘ 0EPS/Sales Surpr. ⓘ -SMA200 ⓘ 11.48% ($29.88)Avg Volume(3M) ⓘ 0.28MPrice ⓘ $33.31
IPO ⓘ 2008/7/7Option/Short ⓘ Yes/YesTrades ⓘ 2193Volume ⓘ 162,494Change ⓘ -0.24%
Company
LKFT LKFTLakefront Biotherapeutics NV ADR | NASD | Biotechnology Deep dive

🧬 A European-based clinical-stage biotech company developing therapeutics for cancer and immune diseases. It develops drug candidates targeting hematologic cancers and autoimmune diseases through differentiated approaches such as cell therapy and immune modulation, and is expanding its pipeline through collaborations with major pharmaceutical companies. This is a clinical-stage biotech that changed its name from the former Galapagos, focusing on the immuno-oncology and autoimmune disease sectors.

Quote

Over the past 1 year, roughly in the middle

8% below its 1-year high.

Now $33.31
52w low$25.6852w high$36.24
52W Range72%
Volume ⓘ 162,494

Traded less than usual. That is 58% of its average volume.

B
Overall · fairly good
We judged 7 of the 8 questions below. 3 rate excellent and 2 need caution.
Not applicable: dividends.
ETFs holding this stock 5 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #85 of 598 in the industry

Based on market cap of $2B.

FAQ

FAQ

LKFT belongs to the Healthcare sector and operates in the Biotechnology industry.

The market cap of LKFT is approximately $2.2B, ranking 1,908 within its sector.

LKFT has a P/E ratio of approximately 2.4x, which can be used to assess its valuation relative to the Healthcare sector average.

LKFT has recorded a 52-week high of $36.24 and a low of $25.68.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels